Dimerix (ASX:DXB) just closed a 2nd licensing deal

Dimerix (ASX:DXB) did it again ASX-listed kidney disease drug developer Dimerix (ASX: DXB) is well positioned to bring its DMX-200 drug to market for Focal Segmental Glomerulosclerosis (FSGS). The drug…

ByMarc Kennis

08

Apr 2024

Uncategorized

Dimerix (ASX:DXB): In Phase 3 for FSGS and so far, so very good!

There aren't many ASX biotech stocks in Phase 3, and even fewer with successful interim data, but Dimerix (ASX:DXB) is one such company. Although it has some way to go…

ByNick Sundich

22

Jan 2024

Uncategorized

FDA approval for ASX health stocks: Which companies are close to the green light in 2024?

FDA approval for ASX health stocks is the dream that just about all emerging companies in the sector are aspiring to. Just over 12 months ago, we predicted that Neuren…

ByNick Sundich

Dimerix (ASX:DXB) just closed a 2nd licensing deal

Dimerix (ASX:DXB): In Phase 3 for FSGS and so far, so very good!

FDA approval for ASX health stocks: Which companies are close to the green light in 2024?

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Dimerix (ASX:DXB) just closed a 2nd licensing deal

Dimerix (ASX:DXB): In Phase 3 for FSGS and so far, so very good!

FDA approval for ASX health stocks: Which companies are close to the green light in 2024?

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Add Your Heading Text Here